The Official Trump (CRYPTO: TRUMP) meme coin project shortlisted the top 220 holders eligible for an exclusive dinner with President Donald Trump on Monday, with top wallets linked to foreign entities.
The company’s shares have gained positive momentum after closing above their 200-day moving average for three consecutive days, with SEBI-registered analyst Kush Ghodasara recommending buying with a stop loss at ₹3,420.
A fire at an abandoned multi-story mattress warehouse near West Baltimore station on Monday evening has suspended all regional rail service, affecting thousands of commuters. Amtrak halted trains between Washington, D.C., and Wilmington, including BWI Airport connections, while MARC commuter lines also face disruptions.
Markets posted one of its strongest sessions of 2025 so far. We’ve had a volatile first half of the year, and we might expect that volatility to continue.
Activist investor Elliott Investment Management scored a victory on Monday when Institutional Shareholder Services recommended investors elect all four of Elliott's director nominees to the Phillips 66 board, bolstering the hedge fund's campaign for strategic changes at the oil refiner.
The trial, which will involve sites in the U.S., Europe, and the Middle East, aims to combine Phase 2B and Phase 3 data for efficacy evaluation of the Miracle trial of Annamycin for relapsed or refractory acute myeloid leukemia.
After such a big move higher last night, I’m expecting a range to develop over the next couple days. Ranges love to rotate, so these rotation trades are likely where the EASY money will be made!
The company shared Phase 1 trial results for CX-2051, an antibody-drug conjugate for advanced colorectal cancer, with 28% of patients achieving confirmed partial responses.
House Republicans on Monday introduced legislation to eliminate the electric vehicle tax credit and repeal fuel efficiency rules, potentially disrupting billions in automaker investments amid growing industry concerns about abrupt policy changes.
Trump’s executive order aims to lower U.S. drug costs by capping prices to match those in other countries, addressing the long-standing issue of Americans paying more for brand-name prescriptions. The policy’s legality remains untested in court.
Tariff news flow, first-tier economic data, and a few earnings reports could decide the day's trading direction, although the momentum is decisively in favor of further gains.
